Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

Published:2019-06-27 Issue:18 Volume:125 Page:3208-3218
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Haddad Robert¹,Concha‐Benavente Fernando²,Blumenschein George³,Fayette Jerome⁴,Guigay Joel⁵,Colevas A. Dimitrios⁶,Licitra Lisa⁷⁸,Kasper Stefan⁹,Vokes Everett E.¹⁰,Worden Francis¹¹,Saba Nabil F.¹²^ORCID,Tahara Makoto¹³,Jayaprakash Vijayvel¹⁴,Lynch Mark¹⁴,Li Li¹⁴,Gillison Maura L.³,Harrington Kevin J.¹⁵,Ferris Robert L.²^ORCID

Affiliation:

1. Dana‐Farber/Harvard Cancer Center Boston Massachusetts

2. Hillman Cancer Center University of Pittsburgh Medical Center Pittsburgh Pennsylvania

3. The University of Texas MD Anderson Cancer Center Houston Texas

4. Centre Leon Berard Lyon France

5. Centre Antoine Lacassagne FHU OncoAge, Université Côte d'Azur Nice France

6. Stanford University Stanford California

7. Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

8. University of Milan Milan Italy

9. West German Cancer Center University Hospital Essen Germany

10. University of Chicago Medical Center Chicago Illinois

11. University of Michigan Ann Arbor Michigan

12. Winship Cancer Institute, Emory University Atlanta Georgia

13. National Cancer Center Hospital East Kashiwa Japan

14. Bristol‐Myers Squibb Princeton New Jersey

15. National Institute for Health Research Biomedical Research Centre, Royal Marsden/Institute of Cancer Research London United Kingdom

Funder

Bristol-Myers Squibb

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32190

Reference20 articles.

1. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

2. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer

3. Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

4. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

5. Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Cited by 75 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders;Oral Oncology;2024-11

2. Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment;Cancer Letters;2024-08

3. Comparison of PD-L1 assays in head and neck carcinoma;Pathology;2024-08

4. Hyper-late major response after 5 years of nivolumab: role of treatment beyond progression in head and neck cancer;Anti-Cancer Drugs;2024-06-28

5. Overcoming Resistance to Standard-of-Care Therapies for Head and Neck Squamous Cell Carcinomas;Cells;2024-06-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3